NO20071924L - Vaksiner mot japansk ecefalittvirus og West Nile virus - Google Patents

Vaksiner mot japansk ecefalittvirus og West Nile virus

Info

Publication number
NO20071924L
NO20071924L NO20071924A NO20071924A NO20071924L NO 20071924 L NO20071924 L NO 20071924L NO 20071924 A NO20071924 A NO 20071924A NO 20071924 A NO20071924 A NO 20071924A NO 20071924 L NO20071924 L NO 20071924L
Authority
NO
Norway
Prior art keywords
virus
ecephalitis
west nile
vaccines against
against japanese
Prior art date
Application number
NO20071924A
Other languages
English (en)
Norwegian (no)
Inventor
Farshad Guirakhoo
Jian Liu
John A Catalan
Thomas P Monath
Konstantin V Pugachev
Original Assignee
Acambis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acambis Inc filed Critical Acambis Inc
Publication of NO20071924L publication Critical patent/NO20071924L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
NO20071924A 2004-10-20 2007-04-16 Vaksiner mot japansk ecefalittvirus og West Nile virus NO20071924L (no)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US62046604P 2004-10-20 2004-10-20
US62094804P 2004-10-21 2004-10-21
US67441505P 2005-04-24 2005-04-24
US67454605P 2005-04-25 2005-04-25
US71892305P 2005-09-19 2005-09-19
PCT/US2005/037369 WO2006044857A2 (en) 2004-10-20 2005-10-19 Vaccines against japanese encephalitis virus and west nile virus

Publications (1)

Publication Number Publication Date
NO20071924L true NO20071924L (no) 2007-07-17

Family

ID=36203650

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20071924A NO20071924L (no) 2004-10-20 2007-04-16 Vaksiner mot japansk ecefalittvirus og West Nile virus

Country Status (13)

Country Link
US (2) US8029802B2 (cg-RX-API-DMAC7.html)
EP (1) EP1809325B1 (cg-RX-API-DMAC7.html)
JP (1) JP4993301B2 (cg-RX-API-DMAC7.html)
KR (1) KR101501162B1 (cg-RX-API-DMAC7.html)
AU (1) AU2005295438B2 (cg-RX-API-DMAC7.html)
CA (1) CA2584228C (cg-RX-API-DMAC7.html)
EA (1) EA015907B1 (cg-RX-API-DMAC7.html)
IL (1) IL182453A0 (cg-RX-API-DMAC7.html)
MY (1) MY148075A (cg-RX-API-DMAC7.html)
NO (1) NO20071924L (cg-RX-API-DMAC7.html)
NZ (1) NZ584079A (cg-RX-API-DMAC7.html)
SG (1) SG156666A1 (cg-RX-API-DMAC7.html)
WO (1) WO2006044857A2 (cg-RX-API-DMAC7.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL371187A1 (en) 2001-06-01 2005-06-13 Acambis, Inc. Chimeric flavivirus vectors
AU2003267937C1 (en) 2002-01-15 2019-08-08 Sanofi Pasteur Biologics, Llc Flavivirus vaccines
JP4683926B2 (ja) 2002-11-15 2011-05-18 サノフィ パスツール バイオロジクス カンパニー ウエストナイルウイルス・ワクチン
US8029802B2 (en) 2004-10-20 2011-10-04 Sanofi Pasteur Biologics Co. Vaccines against Japanese encephalitis virus and West Nile virus
AU2013204985B2 (en) * 2005-04-24 2016-01-28 Sanofi Pasteur Biologics, Llc Recombinant flavivirus vaccines
BRPI0609949A2 (pt) 2005-04-24 2010-05-11 Acambis Inc flavivìrus recombinante, seu uso na preparação de vacina, composição farmacêutica compreendendo o mesmo, molécula de ácido nucléico e método para atenuar candidato a vacina de flavivìrus
AU2007303608B2 (en) 2006-09-29 2013-05-02 Takeda Vaccines, Inc. Norovirus vaccine formulations
EP2086581B1 (en) 2006-11-07 2014-08-13 Sanofi Pasteur Biologics, LLC Stabilization of vaccines by lyophilization
WO2008115314A2 (en) * 2007-01-31 2008-09-25 Sanofi Pasteur Biologics Co. Flavivirus vaccine vector against influenza virus
US10130696B2 (en) 2007-09-18 2018-11-20 Takeda Vaccines, Inc. Method of conferring a protective immune response to norovirus
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
AU2009241354B2 (en) * 2008-04-30 2014-06-12 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Chimeric West Nile/Dengue viruses
SG2013057732A (en) 2008-08-08 2015-02-27 Ligocyte Pharmaceuticals Inc Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity
CA3001374A1 (en) * 2008-11-17 2010-05-20 Vgx Pharmaceuticals, Llc Antigens that elicit immune response against flavivirus and methods of using same
US8968996B2 (en) 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
MX343172B (es) 2009-06-01 2016-10-26 Takeda Vaccines Inc Composiciones y metodos para administracion de vacunas contra virus del dengue.
CA3150404A1 (en) 2009-07-31 2011-02-03 Pnuvax Inc. High yield yellow fever virus strain with increased propagation in cells
US10081795B2 (en) * 2010-03-24 2018-09-25 Research Development Foundation Flavivirus host range mutations and uses thereof
CN101926989A (zh) * 2010-06-29 2010-12-29 西北农林科技大学 表达jev免疫原基因的重组减毒鼠伤寒沙门氏菌载体疫苗及其制备方法
WO2012003320A2 (en) * 2010-07-01 2012-01-05 Research Development Foundation Flavivirus host-range mutations and uses thereof
EA202090699A3 (ru) 2011-07-11 2020-11-30 Такеда Вэксинс, Инк. Композиции, содержащие буфер, вакцины, которые содержат композиции, содержащие буфер, и пути их применения
US9267114B2 (en) * 2012-11-07 2016-02-23 Southern Research Institute Flavivirus envelope protein mutations affecting virion disassembly
US9878031B2 (en) 2012-12-14 2018-01-30 Takeda Vaccines, Inc. Compositions, methods of administration and uses for trivalent dengue virus formulations
JP2016523251A (ja) 2013-06-21 2016-08-08 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． デングウイルスワクチン組成物およびその使用方法
AU2014302282B2 (en) 2013-06-26 2018-09-13 The University Of North Carolina At Chapel Hill Methods and compositions for dengue virus vaccines
WO2016079560A1 (en) 2014-11-21 2016-05-26 Institut Pasteur A live and attenuated japanese encephalitis virus comprising a mutated m protein
AU2015369875A1 (en) 2014-12-22 2017-06-15 Merck Sharp & Dohme Corp. Dengue virus vaccine compositions and methods of use thereof
EA035921B1 (ru) * 2015-07-16 2020-08-31 Бхарат Байотек Интернэшнл Лимитед Вакцинные композиции для профилактики арбовирусных инфекций
WO2020194063A1 (en) * 2019-03-28 2020-10-01 Institut Pasteur A live and attenuated flavivirus comprising a mutated m protein
WO2024254552A1 (en) * 2023-06-08 2024-12-12 Modernatx, Inc. Stabilized flavivirus vaccines

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5173418A (en) 1985-05-10 1992-12-22 Benzon Pharma, A/S Production in Escherichia coli of extracellular Serratia spp. hydrolases
US6676936B1 (en) 1988-07-14 2004-01-13 The United States Of America As Represented By The Department Of Health And Human Services. Chimeric and/or growth-restricted flaviviruses
US6184024B1 (en) 1988-07-14 2001-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
US6962708B1 (en) 1997-02-28 2005-11-08 Acambis, Inc. Chimeric flavivirus vaccines
NZ337522A (en) * 1997-02-28 2001-02-23 St Chimeric flavivirus incorporating yellow fever virus modified such that a prM-E protein of a second flavivirus is expressed, and vaccines for flavivruses
US6589533B1 (en) 1997-09-18 2003-07-08 Research Development Foundation Genetically-engineered alphaviruses, flaviviruses, and bunyaviruses with modified envelope transmembrane glycoproteins and altered host-range phenotype
AU9794198A (en) 1997-10-08 1999-04-27 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Chimeric vaccine against tick-borne encephalitis virus
US7227011B2 (en) * 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
WO2001039802A1 (en) 1999-12-01 2001-06-07 Oravax, Inc. Chimeric flavivirus vaccines
WO2002081753A1 (en) 2001-04-04 2002-10-17 Advanced Research & Technology Institute Method for identifying and characterizing individual dna molecules
WO2003060088A2 (en) 2002-01-15 2003-07-24 Acambis, Inc. Viral vaccine production method
US20050002968A1 (en) 2002-01-15 2005-01-06 Monath Thomas P. Flavivirus vaccines
AU2003267937C1 (en) * 2002-01-15 2019-08-08 Sanofi Pasteur Biologics, Llc Flavivirus vaccines
JP4683926B2 (ja) * 2002-11-15 2011-05-18 サノフィ パスツール バイオロジクス カンパニー ウエストナイルウイルス・ワクチン
US7189403B2 (en) * 2003-06-30 2007-03-13 Institut Pasteur Attenuated flavivirus strains containing a mutated M-ectodomain and their applications
US8029802B2 (en) 2004-10-20 2011-10-04 Sanofi Pasteur Biologics Co. Vaccines against Japanese encephalitis virus and West Nile virus
BRPI0609949A2 (pt) 2005-04-24 2010-05-11 Acambis Inc flavivìrus recombinante, seu uso na preparação de vacina, composição farmacêutica compreendendo o mesmo, molécula de ácido nucléico e método para atenuar candidato a vacina de flavivìrus

Also Published As

Publication number Publication date
MY148075A (en) 2013-02-28
WO2006044857A3 (en) 2006-08-10
EP1809325B1 (en) 2013-11-20
EP1809325A2 (en) 2007-07-25
US8029802B2 (en) 2011-10-04
EA015907B1 (ru) 2011-12-30
JP4993301B2 (ja) 2012-08-08
EA200700904A1 (ru) 2007-12-28
US8691550B2 (en) 2014-04-08
EP1809325A4 (en) 2009-07-22
CA2584228C (en) 2015-05-05
KR101501162B1 (ko) 2015-03-16
HK1106723A1 (en) 2008-03-20
AU2005295438A1 (en) 2006-04-27
AU2005295438B2 (en) 2012-07-05
US20120201852A1 (en) 2012-08-09
IL182453A0 (en) 2007-07-24
US20070269458A1 (en) 2007-11-22
CA2584228A1 (en) 2006-04-27
KR20070072597A (ko) 2007-07-04
WO2006044857A2 (en) 2006-04-27
NZ584079A (en) 2011-10-28
SG156666A1 (en) 2009-11-26
JP2008520187A (ja) 2008-06-19

Similar Documents

Publication Publication Date Title
NO20071924L (no) Vaksiner mot japansk ecefalittvirus og West Nile virus
NO20081999L (no) Forbindelser og fremgangsmater for inhibering av hepatitt C viral replikasjon
TW200745120A (en) Indolobenzazepine HCV NS5B inhibitors
DE602005014628D1 (de) Embolie-teilchen
NO20052493D0 (no) Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og deres anvendelse som farmasoytiske sammensetninger.
NO20070751L (no) Inhibitorer av HCV-replifikasjon
WO2004060308A3 (en) Thiosemicarbazones as anti-virals and immunopotentiators
ATE474827T1 (de) Hcv-replikationshemmer
NO20062146L (no) Nukleosidforbindelser for behandling av virusinfeksjoner
WO2003101397A3 (en) Tetravalent dengue vaccines
DK1948149T4 (da) Formulering, som omfatter metformin og vildagliptin
NO20073065L (no) Injiserbare nanopartikulaere olanzapinformuleringer
NO20082376L (no) Farmasoytiske sammensetninger
IL202978A0 (en) West nile virus vaccine
NO20072055L (no) Fremgangsmater og sammensetninger for behandling av flaviviruser, pestiviruser og hepacivirus
DK1792927T3 (da) Ny blokcopolymer, micelletilberedning og anticancermiddel indeholdende samme som aktiv ingrediens
WO2005082020A3 (en) Flavivirus vaccines
DK1670458T3 (da) 1-Amino-2-oxy-substituerede tetrahydronaphthalenderivater, fremgangsmåder til fremstilling deraf og deres anvendelse som antiphlogistika
NO20080351L (no) Anvendelse av sanglifehrin i HCV
TW200726471A (en) Heteroaryl derivatives for treating viruses
WO2006121466A3 (en) Hcv inhibitors
WO2006017206A3 (en) Flavivirus vaccine
NO20073071L (no) Benzotiazolformuleringer og anvendelse av disse
WO2002072803A3 (en) Subgenomic replicons of the flavivirus dengue
WO2006118607A3 (en) Hcv inhibitors with carbazole structure

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application